From fragmentation to federation: multi-partner OMOP implementation in Uganda enabling global real-world evidence generation
Kanyike F, Nanungi A, Dickinson H, Adam A, Brash J, Do T, Otike C, Bogart M, Asiimwe A, Zandt MV, Mutuluuza Cissy Kityo. From fragmentation to federation: multi-partner OMOP implementation in Uganda enabling global real-world evidence generation. Front Digit Health. 2026 Sep 17;8:1907568. doi: 10.3389/fdgth.2026.1907568. https://doi.org/10.3389/fdgth.2026.1907568
JCRC Publications
Guidance on the clinical management of HIV-1 persistent low-level viremia on antiretroviral treatment: a scoping review and an international Delphi consensus
Tommaso Clemente, Arjen J Stam, Olof Elvstam, Anna Maria Geretti, Richard Harrigan, Milosz Parczewski, Nicola E Mackie, Vincenzo Spagnuolo, Marije Hofstra, Francois Venter, Daniel R Kuritzkes, Josep M Llibre, Robert W Shafer, Jonathan Schapiro, Esteban Martinez, Cissy Kityo-Mutuluuza, Monique Nijhuis, Per Björkman, Charlotte Charpentier, Simon Collins, Huldrych F Günthard, Diego Cecchini, Antonella Castagna, Nele Brusselaers, Annemarie MJ Wensing on behalf of the International Consensus Group on the Clinical Management of Low-Level Viremia. Guidance on the clinical management of HIV-1 persistent low-level viremia on antiretroviral treatment: a scoping review and an international Delphi consensus. Lancet HIV 2026 Published Online June 11, 2026 https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00107-4/abstract
Cabotegravir and Rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial
Cissy Kityo, Ivan K. Mambule, Joseph Musaazi, Simiso Sokhela, Henry Mugerwa, Ibrahim Yawe, Fiona Cresswell, Abraham Siika, Josphat Kosgei, Reena Shah, Logashvari Naidoo, Kimton Opiyo, Caroline Otike, Karlien Möller, Max Okwero, Charity Wambui, Veerle Van Eygen, Perry Mohammed, Fafa Addo Boateng, Nicholas I. Paton, on behalf of the CARES trial team. Cabotegravir and Rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial. Nature Medicine. 2026 Jan;32(1):168-177. doi: 10.1038/s41591-025-04041-7 Epub 04 November 2025. DOI: https://doi.org/10.1038/s41591-025-04041-7
Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial
Turkova Anna, White Ellen, Violari Avy, Mujuru Hilda, Kekitiinwa Adeodata R., Lugemwa Abbas, Kaudha Elizabeth, Na-Rajsima Sathaporn, Ahimbisibwe Grace Miriam, Variava Ebrahim, Archary Moherndran, Akhalwaya Yasmeen, Puthanakit Thanyawee, Bwakura-Dangarembizi Mutsa, Bbuye Dickson, Kasozi Mariam, Liberty Afaaf, Königs, Christoph Welch Steven, Riault Yoann, Bamford Alasdair, Cressey Tim R., Musoke Philippa, Kityo Cissy, Ferrand Rashida Abbas, Giaquinto Carlo et al. Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial. Lancet Child Adolescent Health, March 2026, 2026 Mar;10(3):189-202. doi: 10.1016/S2352-4642(25)00339-6. Epub 2026 Jan 21. 10.1016/S2352-4642(25)00339-6
“If there was no stigma around it, I would tell people”: perspectives of UK youth living with perinatally acquired HIV, their social networks and healthcare professionals on HIV status sharing
Gnan G, Vosper J, Foster C, Seeley J, Musiime Victor, Fidler S, Frize G, Evangeli M. "If there was no stigma around it, I would tell people": perspectives of UK youth living with perinatally acquired HIV, their social networks and healthcare professionals on HIV status sharing. AIDS Care. 2026 Jan 21:1-14. doi: 10.1080/09540121.2026.2614346. Epub ahead of print. PMID: 41563880. https://doi.org/10.1080/09540121.2026.2614346
Characterization of Distinct Monocyte Subtypes and Immune Features Associated with HIV, Tuberculosis, and Coronary Artery Disease in a Ugandan Cohort Using Mass Cytometry
Cobeña-Reyes J, Wanjalla CN, Feria MG, Simmons J, Temu T, Nochowicz C, Arafat SY, Kityo C, Erem G, Longenecker CT, Andorf S, Huaman MA. Characterization of Distinct Monocyte Subtypes and Immune Features Associated with HIV, Tuberculosis, and Coronary Artery Disease in a Ugandan Cohort Using Mass Cytometry. Pathog Immun. 2026 Jan 29;11(1):14-38. doi: 10.20411/pai.v11i1.945. PMID: 41640845; PMCID: PMC12867109. https://doi.org/10.20411/pai.v11i1.945
Kidney disease screening at ART initiation among adults with HIV in Uganda: A missed priority for a high-risk population
Grace Kansiime, Joseph Baruch Baluku, Edwin Nuwagira, Michael Kanyesigye, Paul Stephen Obwoya, Rose Muhindo, Winnie R. Muyindike, Pliers Denis Tusingwire, Henry Mugerwa, Matthew Odera, Monday Busuulwa, Matthew Ssemakadde, Esther C. Atukunda. Kidney disease screening at ART initiation among adults with HIV in Uganda: A missed priority for a high-risk population. Published: February 2, 2026 https://doi.org/10.1371/journal.pgph.0005106
Impact of COVID-19 on New – onset Type 1 diabetes mellitus: A six-year retrospective review from two Paediatric clinics, Kampala, Uganda
Ahabwenki R, Piloya T, Namiiro F, Muzeyi W, Nyangabyaki C, Katairo T, Namugumya A, Nakimera J, Kyekulidde F, Kidega Robert, Ali FN, Mirembe A, Kikaire B, Ndeezi G, Musiime Victor, Kiguli S. Impact of COVID-19 on New - onset Type 1 diabetes mellitus: A six-year retrospective review from two Paediatric clinics, Kampala, Uganda. PLoS One. 2026 Feb 5;21(2):e0341145. doi: 10.1371/journal.pone.0341145. PMID: 41642817; PMCID: PMC12875443. https://doi.org/10.1371/journal.pone.0341145
Tetanus infection in an 11-year-old male with full infant vaccination history: a rare case report
Akello F, Achen S, Najjuma F, Musiime Victor. Tetanus infection in an 11-year-old male with full infant vaccination history: a rare case report. BMC Pediatrics. 2026 Feb 16;26(1):230. doi: 10.1186/s12887-026-06588-x. PMID: 41699542; PMCID: PMC13014842. https://doi.org/10.1186/s12887-026-06588-x
Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in Uganda
Natukunda Eva, Mwaka E, Szubert AJ, Bamford A, Doerholt K, Wandera C, Byaruhanga Spencer, Nambi Esther, Gibb DM, Musiime Victor, Musoke P, Walker AS. Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in Uganda. PLOS Glob Public Health. 2026 Feb 17;6(2):e0005979. doi: 10.1371/journal.pgph.0005979. PMID: 41701698; PMCID: PMC12912597. https://doi.org/10.1371/journal.pgph.0005979
Body Composition Changes in Children Living with HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial
15. Eva Natukunda, Alex J. Szubert, Mutsa Bwakura-Dangarembizi, Veronica Mulenga, Katja Doerholt, Abbas Lugemwa, Spencer Byaruhanga Esther Nambi, Wedu Ndebele, Mary Nyathi, MMed, Diana M. Gibb, Grace Ndeezi, Ann Sarah Walker, Philippa Musoke, Victor Musiime. Body Composition Changes in Children Living with HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial. The Pediatric Infectious Disease Journal, 24 Feb 2026
DOI: https://doi.org/10.1097/inf.0000000000005195
Intentions and attitudes of caregivers towards enrolment of their children and adolescents living with HIV into remission trials involving analytic treatment interruption
Peay HL, Otwombe K, Barnabas S, Barrios-Tascon A, Lain MG, Nhampossa T, Rutebarika Diana, Jupimai T, Archary M, Maiga AI, Violari A, Spyer MJ, Reddy K, Palma P, Pahwa S, Lichterfeld M, Cotton M, Kuhn L. Intentions and attitudes of caregivers towards enrolment of their children and adolescents living with HIV into remission trials involving analytic treatment interruption. J Int AIDS Soc. 2026 Feb;29(2):e70084. doi: 10.1002/jia2.70084. PMID: 41664887; PMCID: PMC12887576. https://doi.org/10.1002/jia2.70084
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ Rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa.
Diana Anena, Elizabeth Chappell, Rashidah Nazzinda, Cecilia Kiilu, Moses Chitsamatanga, Tiyara Arumugam, Alexandra Green, Cissy Kityo Mutuluuza, Mutsa Bwakura Dangarembizi, Abraham Siika, Moherndran Archary, Lungile Jafta, Stella Namukwaya, Janet Seeley, George Akabwai, Henry Mugerwa, et al. Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ Rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa. Contemporary Clinical Trials, March 2026 https://doi.org/10.1016/j.cct.2025.108213
The process of developing an HIV disclosure intervention for youth with perinatally acquired HIV: The HIV Empowering Adults’ Decisions to Share – UK/Uganda Project (Heads-Up)
Evangeli M, Gnan G, Musiime Victor, Fidler S, Seeley J, Frize G, Uwizera A, Robinson J, Foster C. The process of developing an HIV disclosure intervention for youth with perinatally acquired HIV: The HIV Empowering Adults' Decisions to Share - UK/Uganda Project (Heads-Up). Glob Public Health. 2026 Dec 31;21(1):2640768. doi: 10.1080/17441692.2026.2640768. Epub 2026 Mar 9. PMID: 41800659. https://doi.org/10.1080/17441692.2026.2640768
Tuberculosis research principles and priorities in children and adolescents: an international consensus statement
Sekadde MP, Chiang SS, Brands A, Casenghi M, Chabala C, Graham SM, Masini T, Seddon JA, Verkuijl SE, Viney K, Marais BJ; Child and Adolescent TB Working Group (Shakil Ahmed, Pauline M. Amuge, et al). Tuberculosis research principles and priorities in children and adolescents: an international consensus statement. Lancet Child Adolesc Health. 2026 Mar 23:S2352-4642(26)00046-5. doi: 10.1016/S2352-4642(26)00046-5. Epub ahead of print. PMID: 41887231. https://doi.org/10.1016/s2352-4642(26)00046-5
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial
Kekitiinwa AR, Jennings A, Bwakura-Dangarembizi M, Kityo C, Siika A, Archary M, Green A, Jafta L, Akabwai GP, Mujuru HA, Mugerwa H, Kiilu C, Mngqibisa R, Seeley J, Nazzinda R, Apoto N, Walker S, Burger D, Giaquinto C, Okello RB, Musoro G, Wambui C, Arumugam T, Conway M, Van Looy N, South A, Bamford A, Thomason MJ, Ford D, Pett SL; BREATHER Plus trial team. Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial. Lancet HIV. 2026 Apr 7:S2352-3018(25)00326-1. doi: 10.1016/S2352-3018(25)00326-1. Epub ahead of print. PMID: 41962560. https://doi.org/10.1016/s2352-3018(25)00326-1
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial
Wyncoll J, Kamolrattana R, Archary M, Mujuru HA, Kekitiinwa AR, Violari A, Na-Rajsima S, Lugemwa A, Variava E, Cotton M, Kityo CM, Königs C, Behuhuma NO, Welch S, Saïdi Y, Marques L, Ahimbisibwe GM, Houlden L, Giaquinto C, Rojo P, Gibb DM, Puthanakit T, Turkova A, White E, Ford D. Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial. Clin Infect Dis. 2026 Apr 10:ciag232. doi: 10.1093/cid/ciag232. Epub ahead of print. PMID: 41967904. https://doi.org/10.1093/cid/ciag232
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial
Hilda Angela Mujuru,a Ellen White, Adeodata R. Kekitiinwa, Abbas Lugemwa, Cissy Kityo, Ebrahim Variava, Moherndran Archary, Mark Cotton, Avy Violari, Grace Miriam Ahimbisibwe, Pradthana Ounchanum, Thanyawee Puthanakit, Chaiwat Ngampiyaskul, Robin Kobbe, Srini Bandi, Suparat Kanjanavanit, Cristina Epalza, Mutsawashe Bwakura-Dangarembizi, Dickson Bbuye, Mariam Kasozi, Elizabeth Kaudha, Tim R. Cressey, Carlo Giaquinto, Lungile Jafta, Alasdair Bamford, and Deborah Ford, on behalf of the ODYSSEY trial team , Pablo Rojo, Diana M. Gibb, Anna Turkova. Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial. Open Forum Infectious Diseases, Volume 13, Issue 5, May 2026, ofag266, https://doi.org/10.1093/ofid/ofag266
Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios
Robert W. Shafer, Kaiming Tao, Tom Loosli, Ana Abecasis, Daniele Armenia, George Bwire, Ricardo Sobhie Diaz, Joseph Fokam, Amalia Giron, Seth Inzaule, Rami Kantor, Cissy Kityo, Roger D. Kouyos, Swarali Kurle, Anne-Genevieve Marcelin, Roger Paredes, Martine Peeters, Victor F. Pimentel, Jonathan M. Schapiro, Kim Steegen, Marco Vitoria, Annemarie M. Wensing, Neil Parkin, Michael R. Jordan. Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios
Viruses 2026, 18(6), 588; https://doi.org/10.3390/v18060588
Clients’ Perspectives on Switching from Old Stable ART Regimens to New Dolutegravir-based Regimen at Joint Clinical Research Centre Uganda
Francis Kanyike, Kenneth Katende Kidonge, Sarah Nabukeera, John Bosco M. Ddamulira, Joseph K. B. Matovu "Clients' Perspectives on Switching from Old Stable ART Regimens to New Dolutegravir-based Regimen at Joint Clinical Research Centre Uganda," Published: 03 July 2026. Sci Rep (2026). https://doi.org/10.1038/ s41598-026-60583-x
Paediatric Drug Optimization for Sickle Cell Disease: priorities for research and development in children.
Tiziana Masini, Sarah Charnaud, Prof Jane S Hankins, Cissy Kityo, Prof Julie Makani MD, Prof Claudia R Morris, Prof Isaac Odame, Anna Laura Ross, Giulia Segafredo, Omary Said Ubuguyu, Nuhu Omeiza Yaqub, Wilson Milton Were. Paediatric Drug Optimization for Sickle Cell Disease: priorities for research and development in children. Lancet Child Adolesc Health 2026; 10: 755–64.https://doi.org/10.1016/S2352-4642(26)00159-8
The imperative for increased investment for an HIV cure
Remko van Leeuwen, Françoise Barré-Sinoussi, Michaela Müller-Trutwin, Asier Sáez-Cirión, Monique Nijhuis, Sharon R Lewin, Thumbi Ndung'u, Florence Riako-Anam, Mitchell Warren, Izukanji Sikazwe, Birgit Poniatowski, Beatriz Grinsztejn, Cissy Kityo, Masen Davis, Ole S Søgaard, Marcus Altfeld, Javier Martinez-Picado, Linos Vandekerckhove, Andrea Gramatica, Devin Sok, Simon Collins, Yazdan Yazdanpanah. The imperative for increased investment for an HIV cure. The Lancet HIV, volume 12, issue 10. October 2025. DOI: 10.1016/S2352-3018(25)00193-6
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial
Cissy Kityo, Ivan K. Mambule, Joseph Musaazi, Simiso Sokhela, Henry Mugerwa, Ibrahim Yawe, Fiona Cresswell, Abraham Siika, Josphat Kosgei, Reena Shah, Logashvari Naidoo, Kimton Opiyo, Caroline Otike, Karlien Möller, Max Okwero, Charity Wambui, Veerle Van Eygen, Perry Mohammed, Fafa Addo Boateng, Nicholas I. Paton, on behalf of the CARES trial team. Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial. Nature Medicine. 04 November 2025. DOI: https://doi.org/10.1038/s41591-025-04041-7
The Association of Mild Kidney Disease with Coronary Artery Disease Is Stronger for People Living With HIV
Doshi Shradha, Richardson Barbra A., Nazzinda, Rashidah, Mugerwa Henry, Bittencourt Marcio Sommer, Erem Geoffrey, Narendrula Aparna, Farquhar Carey, Kityo Cissy, Longenecker Chris T. The Association of Mild Kidney Disease with Coronary Artery Disease Is Stronger for People Living With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 101(1): p 95-102, January 1, 2026. DOI: 10.1097/QAI.0000000000003765 https://journals.lww.com/jaids/abstract/2026/01010/the_association_of_mild_kidney_disease_with.11.aspx
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
Anena Diana, Chappell Elizabeth, Nazzinda Rashidah, Kiilu Cecilia, Chitsamatanga Moses, Arumugam Tiyara, Green Alexandra, Green Alexandra, Kityo Cissy, Bwakura-Dangarembizi Mutsa F., Siika Abraham, M. Archary Moherndran, Jafta Lungile, Namukwaya Stella, Seeley Janet, Akabwai George Patrick, Mugerwa Henry, et al . Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa. Submitted 30 October 2025. Pre-print Available at SSRN: https://ssrn.com/abstract=5671058 or http://dx.doi.org/10.2139/ssrn.5671058
Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial
Turkova Anna, White Ellen, Violari Avy, Mujuru Hilda, Kekitiinwa Adeodata R., Lugemwa Abbas, Kaudha Elizabeth, Na-Rajsima Sathaporn, Ahimbisibwe Grace Miriam, Variava Ebrahim, Archary Moherndran, Akhalwaya Yasmeen, Puthanakit Thanyawee, Bwakura-Dangarembizi Mutsa, Bbuye Dickson, Kasozi Mariam, Liberty Afaaf, Königs, Christoph Welch Steven, Riault Yoann, Bamford Alasdair, Cressey Tim R., Musoke Philippa, Kityo Cissy, Ferrand Rashida Abbas, Giaquinto Carlo et al. Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial. Pre-print in The Lancet, Available at SSRN: https://ssrn.com/abstract=5413584 or http://dx.doi.org/10.2139/ssrn.5413584 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5413584
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa
Fredrick Katongole, Tiyara Arumugam, Angus Jennings, Constatine Mutata, Patrick Ssebunya, Charity Wamboi, Alexandra Green, Mutsa Bwakura-Dangarembizi, Cissy Kityo, Abraham Siika, et al, and the BREATHER Plus Trial Team. BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa. Contemporary Clinical Trials. Epublished 29 May 2025. August 2025. DOI: 10.1016/j.cct.2025.107963
Short-cycle therapy (weekends-off) on dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a randomised, open-label, 96-week non-inferiority trial
Adeodata R. Kekitiinwa; Angus Jennings; Mutsa Bwakura Dangarembizi; Cissy Kityo; Abraham Siika; Alexandra Green; George Patrick Akabwai; Hilda Angela Mujuru; Henry Mugerwa; Cecilia Kiilu; Rosie Mngqibisa; Janet Seeley; Rashidah Nazzinda; Naomi Apoto; Resty Babirye Okello. Short-cycle therapy (weekends-off) on dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a randomised, open-label, 96-week non-inferiority trial. The Lancet HIV, Published 29 October 2025.
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial
Lisanne A.H Bevers, Gabriela Toledo, Muzamil Kisekka, Elizabeth Kaudha, Grace M. Ahimbisibwe, Isabella Depres, Tiyara Arumugam, Ebrahim Variava, Avy Violari, Iona White, Dickson Bbuye, Annet Nanduudu, Enoch Mulwanyi, Pauline Amuge, Diana A. Rutebarika, Adeodata R. Kekitiinwa, Cissy Kityo, et al, on behalf The D3 Trial Team. Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, Randomised, non-inferiority D3/PENTA21 trial. eBioMedicine, volume 120, The Lancet Discovery Science. September 03 2025. DOI: 10.1016/j.ebiom.2025.105929
Model-based evaluation of the interaction between ritonavirboosted atazanavir and rifampicin in Ugandan adults with HIV
Allan Kengo, Juan Eduardo, Resendiz-Galvan, Letisha Najjemba, Henry Mugerwa, Amedeo De Nicolo, et al. Model-based evaluation of the interaction between ritonavir-boosted atazanavir and rifampicin in Ugandan adults with HIV. British Journal of Clinical Pharmacology, 91(12):3471-3481. December 2025. DOI: 10.1002/bcp.70195
